Home
/
Moderna, Inc.
/
Financials
/
Quarterly
Moderna, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Moderna, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2023
Jun 30, 2023
$344.00M
Aug 3, 2023
Q1
2023
Mar 31, 2023
$1.86B
May 4, 2023
Q3
2022
Sep 30, 2022
$3.36B
Nov 3, 2022
Q2
2023
Jun 30, 2022
$4.75B
Aug 3, 2023
Q1
2023
Mar 31, 2022
$6.07B
May 4, 2023
Q3
2022
Sep 30, 2021
$4.97B
Nov 3, 2022
Q2
2022
Jun 30, 2021
$4.35B
Aug 3, 2022
Q1
2022
Mar 31, 2021
$1.94B
May 4, 2022
Q3
2021
Sep 30, 2020
$157.00M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$67.00M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$8.00M
May 6, 2021
Q3
2020
Sep 30, 2019
$17.05M
Oct 30, 2020
Q2
2020
Jun 30, 2019
$13.08M
Aug 6, 2020
Q1
2020
Mar 31, 2019
$16.03M
May 7, 2020
Q3
2019
Sep 30, 2018
$41.76M
Nov 6, 2019
Q2
2019
Jun 30, 2018
$28.85M
Aug 8, 2019
Q1
2019
Mar 31, 2018
$29.04M
May 9, 2019
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.02B
Nov 6, 2025
Q2
2025
Jun 30, 2025
$142.00M
Aug 1, 2025
Q1
2025
Mar 31, 2025
$108.00M
May 1, 2025
Q3
2025
Sep 30, 2024
$1.86B
Nov 6, 2025
Q2
2025
Jun 30, 2024
$241.00M
Aug 1, 2025
Q1
2025
Mar 31, 2024
$167.00M
May 1, 2025
Q3
2024
Sep 30, 2023
$1.83B
Nov 7, 2024
Q2
2024
Jun 30, 2023
$344.00M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$1.86B
May 2, 2024
Q3
2023
Sep 30, 2022
$3.36B
Nov 3, 2023
Q3
2019
Sep 30, 2019
$17.05M
Nov 6, 2019
Q2
2019
Jun 30, 2019
$13.08M
Aug 8, 2019
Q1
2019
Mar 31, 2019
$16.03M
May 9, 2019
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($200.00M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($825.00M)
Aug 1, 2025
Q1
2025
Mar 31, 2025
($971.00M)
May 1, 2025
Q3
2025
Sep 30, 2024
$13.00M
Nov 6, 2025
Q2
2025
Jun 30, 2024
($1.28B)
Aug 1, 2025
Q1
2025
Mar 31, 2024
($1.18B)
May 1, 2025
Q3
2024
Sep 30, 2023
($3.63B)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($1.38B)
Aug 1, 2024
Q1
2024
Mar 31, 2023
$79.00M
May 2, 2024
Q3
2023
Sep 30, 2022
$1.04B
Nov 3, 2023
Q2
2023
Jun 30, 2022
$2.20B
Aug 3, 2023
Q1
2023
Mar 31, 2022
$3.66B
May 4, 2023
Q3
2022
Sep 30, 2021
$3.33B
Nov 3, 2022
Q2
2022
Jun 30, 2021
$2.78B
Aug 3, 2022
Q1
2022
Mar 31, 2021
$1.22B
May 4, 2022
Q3
2021
Sep 30, 2020
($233.00M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($117.00M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($124.00M)
May 6, 2021
Q3
2020
Sep 30, 2019
($123.22M)
Oct 30, 2020
Q2
2020
Jun 30, 2019
($134.94M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($260.00M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($907.00M)
Aug 1, 2025
Q1
2025
Mar 31, 2025
($1.05B)
May 1, 2025
Q3
2025
Sep 30, 2024
($70.00M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($1.36B)
Aug 1, 2025
Q1
2025
Mar 31, 2024
($1.27B)
May 1, 2025
Q3
2024
Sep 30, 2023
($2.01B)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($1.87B)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($366.00M)
May 2, 2024
Q3
2023
Sep 30, 2022
$1.17B
Nov 3, 2023
Q2
2023
Jun 30, 2022
$2.45B
Aug 3, 2023
Q1
2023
Mar 31, 2022
$4.23B
May 4, 2023
Q3
2022
Sep 30, 2021
$3.56B
Nov 3, 2022
Q2
2022
Jun 30, 2021
$3.06B
Aug 3, 2022
Q1
2022
Mar 31, 2021
$1.27B
May 4, 2022
Q3
2021
Sep 30, 2020
($235.00M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($122.00M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($131.00M)
May 6, 2021
Q3
2020
Sep 30, 2019
($130.76M)
Oct 30, 2020
Q2
2020
Jun 30, 2019
($143.71M)
Aug 6, 2020